DEVELOPMENT OF MULTI-NUCLEAR COILS FOR BREAST SPECTROSCOPY AT 7T

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 磁共振的最新发展有可能为癌症患者或有癌症风险的患者提供更敏感和可靠的诊断信息。德克萨斯大学西南医学中心很幸运地在2007年收购了一台7特斯拉成像和光谱系统。虽然在光谱灵敏度和患者分辨率方面的预期好处已经实现，但我们了解到，获取射频(R.F.)线圈是严重限制7特斯拉仪器在临床癌症研究中应用的关键瓶颈。德克萨斯农工大学拟议的工程项目将瞄准并行成像和高场光谱等技术，这些技术具有巨大的潜力，但尚未过渡到癌症研究或临床护理。我们提出了在7T无创体内人体代谢图谱的发展。乳腺癌和脑瘤将是我们研究的最初目标，但这些方法也适用于其他癌症。有三个项目： 1.将升级7T系统，并将构建线圈，以优化乳腺癌和累及脑部的恶性肿瘤的临床研究的成像和光谱。将完成四个相互关联的子项目：a)7T系统将于2010年初升级为双通道1H传输系统。B)两个R.F.用于乳房光谱分析的线圈将在德克萨斯农工大学设计和建造。这两个线圈都将具有1H成像和去耦合的双通道1H传输能力。一个线圈将针对1H解耦和31P检测进行优化，另一个线圈将针对1H解耦和13C检测进行优化。31P MRS将用于研究肿瘤线粒体功能和磷胆碱浓度，13C MRS将用于追踪癌症中的脂肪代谢和其他途径。设计标准是将最佳的13C或31P波谱与单侧乳房的1H成像相结合。C)将构建一个双通道发射/接收线圈，以优化乳房的1H成像。我们的目标是为乳房和腋窝制作一流的1H图像和1H光谱。该线圈将用于乳房成像和胆碱、脂肪含量、病变脂肪成分和其他代谢物的光谱分析。D)一个双通道R.F.将建立和实施脑内1H成像和光谱分析的线圈系统，用于原发和转移性脑恶性肿瘤的研究。 2.评价~1H、~(13)C和~(31)P核磁共振波谱在乳腺病变诊断中的作用，以及这些方法在监测治疗中的作用。增加的磷胆碱(通过31P核磁共振)和总胆碱(通过1H核磁共振)将被评估为乳房小病变的生物标志物和治疗反应的指标。13C核磁共振将非侵入性地测量乳腺肿瘤的化学成分，以测试13C检测到的脂肪成分或其他生物标志物在恶性病变中是否与正常组织不同。 3.将评估7T的~1H核磁共振波谱在治疗低级别胶质瘤、胶质母细胞瘤和转移瘤中的作用。我们将检验这一假设，即对于脑肿瘤患者，高分辨率光谱学将在比目前标准磁共振成像可检测到的时间点更早地识别肿瘤进展。 其目的是利用德克萨斯A&M大学和德克萨斯大学西南分校的优势来开发独特的技术，并评估这项技术在癌症护理中的作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recent developments in magnetic resonance have the potential to provide much more sensitive and reliable diagnostic information for patients with cancer or at risk for cancer. UT Southwestern Medical Center was fortunate to acquire a 7 Tesla imaging and spectroscopy system in 2007. While the anticipated benefits in terms of spectral sensitivity and resolution in patients have been fulfilled, we learned that acquisition of radiofrequency (r.f.) coils is a critical bottleneck that severely limits the utility of the 7 Tesla instrument in clinical cancer research. The proposed engineering projects at Texas A & M University will target techniques such as parallel imaging and high field spectroscopy that have enormous potential but have not yet transitioned into cancer research or clinical care. We propose the development of non-invasive in vivo human metabolic profiling at 7T. Breast cancer and brain tumors will be the initial targets of our investigation, but these methods are applicable in other cancers. There are three projects: 1. The 7T system will be upgraded and coils will be constructed to optimize imaging and spectroscopy for clinical studies of breast cancer and malignancies involving the brain. Four interrelated subprojects will be accomplished: a) The 7T system will be upgraded to a dual channel 1H transmit system in early 2010. b) Two r.f. coils for spectroscopy of the breast will be designed and constructed at Texas A & M University. Both coils will have the capability of dual channel 1H transmit for 1H imaging and decoupling. One coil will be optimized for 1H decoupling and detection of 31P and the other will be optimized for 1H decoupling and detection of 13C. 31P MRS will be used to study tumor mitochondrial function and phosphocholine concentrations and 13C MRS will be used for tracing fat metabolism and other pathways in cancers. The design criteria will be optimal 13C or 31P spectroscopy integrated with 1H imaging of the unilateral breast. c) One dual channel transmit/receive coil will be constructed for optimized 1H imaging of the breast. The goal is to produce superb 1H images and 1H spectroscopy of the breast and axilla. The coil will be used for breast imaging and spectroscopy of choline, fat content, fat composition of lesions and other metabolites. d) One dual-channel r.f. coil system for 1H imaging and spectroscopy in the brain will be constructed and implemented for research in primary and metastatic brain malignancies. 2. The role of 1H, 13C and 31P NMR spectroscopy in diagnosis of breast lesions and the role of these methods in monitoring therapy will be evaluated. Increased phosphocholine (by 31P NMR) and total choline (by 1H NMR) will be evaluated as biomarkers of small breast lesions and indicators of therapeutic response. The chemical composition of breast tumors will be measured noninvasively by 13C NMR to test whether fat composition or other biomarkers detected by 13C differ in malignant lesions compared to normal tissue. 3. The role of 1H NMR spectroscopy at 7T in management of low grade gliomas, glioblastoma, and metastatic tumors will be evaluated. We will test the hypothesis that for patients with brain tumors, high resolution spectroscopy will identify tumor progression at an earlier time point than currently detectable with standard MR imaging. The intent is to leverage the strengths of Texas A & M University and of UT Southwestern to develop unique technology and to evaluate the role of this technology for cancer care.